Programmed death-ligand 1 (PDL-1) has been shown to be increased on AML blasts at relapse (23), PD-1 high T cell phenotypes predict relapse after transplant (38), and PD-1 checkpoint blockade has shown some promise in treating AML patients who relapsed after transplant (39). Here, PDCD1 is linked to acute myeloid leukemia.